FDA
-
-
-
-
-
-
-
American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular
-
-
-
-
-
-
-
Amarin Reports Fourth Quarter and Full Year 2025 Financial Results
-
-
-
-
-
-
-
Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 20
-
-
-
-
-
-
-
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025
-
-
-
-
-
-
-
Amarin Reports First Quarter 2025 Financial Results
-
-
-
-
-
-
-
Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol
-
-
-
-
-
-
-
Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update
-
327,169 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

